CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
Year: 2016
Type: article
Source: Annals of Oncology
Institutions: Erasmus MC, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Epic Sciences (United States), Sanofi (France), University Medical Center Hamburg-Eppendorf, Azienda Ospedaliera San Camillo-Forlanini, Cliniques Universitaires Saint-Luc, Asklepios Klinik Altona, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Sanofi
OpenAlex ID: W2587582396